Compare iShares Bitcoin Trust (IBIT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Viatris Inc — how do they compare? iShares Bitcoin Trust trades at $37.66, while Viatris Inc trades at $17.3 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while iShares Bitcoin Trust pays none, and Viatris Inc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| IBIT | VTRS | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $71.29 | $17.39 |
52-Week Low | $33.29 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $36.89, up 1.49% with neutral technical signals. The stock shows mixed momentum with bearish moving averages but neutral oscillators. Recent news highlights IBIT's position as a leading Bitcoin ETF with $44.9 billion in assets under management, surpassing Fidelity's competing fund. The ETF faces headwinds from significant outflows in June 2026 but maintains institutional interest as a preferred Bitcoin exposure vehicle.
Outlook remains cautious amid Bitcoin market volatility and ETF outflow pressures. Investment opportunity lies in IBIT's dominant market position and institutional adoption, balanced against cryptocurrency market risks and competitive ETF landscape. Key risks include Bitcoin price sensitivity and regulatory uncertainty affecting fund flows.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
